Pharma Focus Asia

Resilience and Lifera Plan for New Manufacturing Facility in Riyadh, Saudi Arabia


Resilience and Lifera plan for new biopharma manufacturing capacity in Riyadh, Saudi Arabia.


The proposed biopharma manufacturing facility represents a significant step towards building resilience and enhancing the lifera plan for the development of the biopharmaceutical industry.

The key features of this facility is its capacity to support the aseptic filling of a wide range of pharmaceutical products, including inactivated and bacterial vaccines, mRNA vaccines, monoclonal antibodies, plasma-derived products, and large molecules.

With a target production capacity of more than 125 million units annually, this facility will significantly contribute to meeting the growing demand for these essential medical products. 

Initially focusing on manufacturing priority molecules, the facility also has strategic plans to export its products to the Gulf Cooperation Council (GCC) countries.

By advancing biopharmaceutical supply chains and enhancing manufacturing capabilities, this project aims to ensure a more reliable and robust response to public health crises and healthcare needs worldwide.


Name  National Resilience & Lifera
Type  New Construction

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference